ICD10 code of Multiple Endocrine Neoplasia and ICD9 code

Multiple Endocrine Neoplasia (MEN) is classified under ICD-10 code D44.8, which covers neoplasms of other and unspecified endocrine glands. In the older ICD-9-CM classification system, Multiple Endocrine Neoplasia is primarily categorized under code 258.0 (Multiple endocrine adenomatosis and related syndromes).

What are the different types of Multiple Endocrine Neoplasia?

Clinically, Multiple Endocrine Neoplasia is a group of rare, inherited disorders that cause tumors in endocrine glands, such as the parathyroid, pancreas, and pituitary. The two primary forms are MEN1 and MEN2. MEN1 is characterized by tumors in the parathyroid glands, pancreas, and pituitary gland. Multiple Endocrine Neoplasia type 2 (MEN2) is further subdivided into MEN2A and MEN2B, which are strongly associated with medullary thyroid carcinoma and pheochromocytoma. Understanding these specific classifications is essential for coordinating care, as surveillance protocols differ significantly between types.

How is Multiple Endocrine Neoplasia diagnosed and coded?

Diagnosis of Multiple Endocrine Neoplasia typically involves a combination of biochemical testing—such as measuring calcium, parathyroid hormone, or calcitonin levels—and genetic testing to identify mutations in the MEN1 or RET genes. When a physician submits medical billing or health records, they use specific codes to reflect these findings:

• ICD-10-CM: D44.8 (Neoplasms of other and unspecified endocrine glands) is the standard for Multiple Endocrine Neoplasia.


• ICD-9-CM: 258.0 (Multiple endocrine adenomatosis and related syndromes) was historically used for this condition.


• Genetic Coding: Diagnostic reports may also include specific gene mutation codes (e.g., Z82.71 for family history of genetic disease) to support clinical necessity for genetic screening.

Is Multiple Endocrine Neoplasia hereditary?

Yes, Multiple Endocrine Neoplasia is an autosomal dominant genetic condition. This means that an affected individual has a 50% chance of passing the causative gene mutation to each of their children. Because of this inheritance pattern, clinical guidelines strongly recommend cascade genetic screening for all first-degree relatives of a patient diagnosed with Multiple Endocrine Neoplasia. Early identification allows for proactive monitoring, which is life-saving given the potential for malignancy in conditions like MEN2.

How does the community support those with Multiple Endocrine Neoplasia?

Living with a complex condition like Multiple Endocrine Neoplasia can feel isolating due to the rarity of the diagnosis. At DiseaseMaps.org, we have 137 people with Multiple Endocrine Neoplasia who have joined the community to share their experiences and navigate the challenges of lifelong endocrine surveillance. Connecting with others who understand the burden of frequent blood draws, imaging scans, and surgical consultations provides invaluable emotional support that clinical care alone cannot offer.

Next steps

• Consult with an endocrinologist or a clinical geneticist to confirm your specific subtype of Multiple Endocrine Neoplasia.


• Request a formal genetic counseling session to discuss the implications for your family members.


• Join the DiseaseMaps.org community to connect with other patients and caregivers navigating similar diagnostic and treatment journeys.


• Ensure your medical records are updated with the accurate ICD-10 code (D44.8) to facilitate appropriate insurance coverage for your surveillance screenings.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases (GARD) Information Center: Multiple Endocrine Neoplasia.


• Orphanet: Rare Disease Database (ORPHA: 2454).


• Online Mendelian Inheritance in Man (OMIM): Entry #131100 (MEN1) and #171400 (MEN2).


• American Association of Clinical Endocrinology (AACE) Clinical Practice Guidelines for Endocrine Tumors.